Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Eliquis Cases Over Bleeding Risk in Jeopardy Following Court Order Granting Dismissal May 12, 2017 Austin Kirk Add Your Comments The U.S. District Judge recently assigned to preside over all federal Eliquis injury lawsuits has granted a motion to dismiss filed by the drug makers, which may impact dozens of other claims brought on behalf of individuals nationwide who experienced uncontrollable bleeding problems. In February, the U.S. Judicial Panel on Multidistrict Litigation (JPML) established consolidated pretrial proceedings for all federal Eliquis cases, which involve common allegations that Bristol-Myers Squibb and Pfizer failed to adequately warn consumers and the medical community about the bleeding risks associated with their novel oral anticoagulant. About 80 cases filed in U.S. District Courts nationwide have been centralized before U.S. District Judge Denise L. Cote in the Southern District of New York as part of a federal MDL, or multidistrict litigation. Learn More About Eliquis Lawsuit Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Eliquis Lawsuit Learn More SEE IF YOU QUALIFY FOR COMPENSATION Each of the plaintiffs indicate that the side effects of Eliquis caused them to suffer severe or fatal bleeding problems, alleging that the drug makers withheld information about the lack of an antidote to reverse the blood thinning effects of the drug, and failed to provide proper recommendations regarding monitoring to maintain a safe dose. In an order (PDF) issued in May 8, Judge Cote struck an early and severe blow to the litigation, granting a motion to dismiss filed by the drug makers in an Eliquis case brought by plaintiff Charlie Utts, who experienced severe gastrointestinal bleeding after using the controversial drug. Judge Cote rejected arguments presented by Utts in an amended complaint, finding that the warnings provided on the Eliquis label were sufficient as a matter of law, resulting in the dismissal of the case. The court found that the lack of an antidote was disclosed to the FDA when the drug was approved, and disclosed in the drug labeling. In addition, Judge Cote found that Utt failed to allege sufficient evidence to establish that inadequate warnings were provided about the proper dosing recommendations, or that better warnings should have been provided about the importance of monitoring patients during treatment. “The plaintiffs have not identified any research or other clinical work that recommends another dosage strategy than that currently described on the label, or explains what specialized monitoring of a patient would accomplish,” wrote Judge Cote in the 85 page opinion. “These two complaints concern features of the design of the drug that were well known to the FDA when it approved the drug.” The decision will have a major impact on the dozens of other cases pending before Judge Cote, as well as hundreds of additional lawsuit currently under investigation by Eliquis injury lawyers. In a separate order (PDF) issued on May 9, Judge Cote indicated that plaintiffs in all other actions pending in the Eliquis litigation have until May 23 to file an amended complaint and to show cause why their cases should not be dismissed based on the same analysis in the Utts opinion. Further, any individuals who bring a future Eliquis case in the federal MDL must file a memorandum within fourteen days explaining why the claim should not be dismissed for the same reasons. Plaintiffs are expected to appeal the dismissal of the Eliquis cases, arguing that they should be permitted to conduct discovery in the litigation and proceed with the claims. The allegations raised in the Eliquis lawsuits are similar to those presented in more than 18,000 Xarelto lawsuits filed against the makers of that competing novel oral anticoagulant, which was introduced about a year earlier. Plaintiffs in those cases also argue that the manufacturers failed to adequately warn about the bleeding risk, withheld information about the lack of an antidote and provided false and misleading information that led to improper monitoring during treatment. After the judge presiding over the Xarelto cases rejected a similar motion to dismiss based on federal pre-emption, a series of early trial dates will be held this year in the federal court system, which are designed to help gauge how juries will respond to certain evidence and testimony that may be presented. Following the bellwether trials, if Xarelto settlements or another resolution for the litigation is not reached, thousands of individual cases may be set for trial dates nationwide. Tags: Bleeding, Blood Thinner, Bristol Myers Squibb, Eliquis, Pfizer, Xarelto Image Credit: | More Eliquis Lawsuit Stories Eliquis More Effective At Preventing Recurring Blood Clots, Embolism, Than Xarelto: Study December 22, 2021 Eliquis Useful In Preventing Blood Clots, But Side Effects Include Major Bleeding Risks: Study December 26, 2018 FDA Approves AndexXa as Reversal Agent For Xarelto, Eliquis May 7, 2018 1 Comments Angela May 30, 2017 I was involved with a case over eloquis for my mother. I just got a certified letter today (5/317) stating the claim was dismissed. I fully intend to appeal, but reading the above, I haven’t been given adequate notice to appeal since it states plaintiffs had until 5/23. I need to obtain counsel my lawyer isn’t willing to appeal. Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCommentsThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Lawyers To Select 50 Suboxone Dental Lawsuits for Next Phase of MDL Bellwether Discovery (Posted: today) As lawyers continue to review records on more than 500 Suboxone tooth decay lawsuits, the MDL judge has outlined the process for identifying a smaller group that will move into the next discovery phase. MORE ABOUT: SUBOXONE TOOTH DECAY LAWSUIT500 Suboxone Tooth Decay Cases Randomly Selected for Bellwether Record Collection Pool (04/24/2025)Status of Suboxone Tooth Loss Lawsuits To Be Reviewed at MDL Conference (04/16/2025)Prenatal Opioid Exposure May Result in Smaller Brains Among Newborns: Study (04/14/2025) Hair Relaxer Lawsuits MDL Judge Seeks Status Report on Discovery Proceedings (Posted: yesterday) A federal judge wants lawyers involved in hair relaxer lawsuits to provide an update this week on the status of discovery proceedings for a pool of cases being considered for bellwether trial dates. MORE ABOUT: HAIR RELAXER LAWSUITFormaldehyde Found in Range of Personal Care Products Used Primarily by Black and Latina Women (05/14/2025)Lawyers Selected 32 Hair Relaxer Lawsuits for Bellwether Discovery in MDL (05/13/2025)Hair Relaxer Settlement Master Appointed To Oversee Negotiations To Resolve Cancer Lawsuits (04/29/2025) Covidien Parietex Optimized Composite (PCOx) Hernia Mesh Lawsuits To Be Prepared for Trial (Posted: yesterday) Two Covidien Parietex Optimized Composite hernia mesh lawsuits have been chosen to be prepared to potentially serve as the third Covidien hernia mesh bellwether trial. MORE ABOUT: HERNIA MESH LAWSUITSecond Bellwether Trial in Covidien Hernia Mesh Lawsuit MDL Set for July 2026 (05/14/2025)Covidien Mesh Lawsuit Set For Trial in Feb. 2026, Over Defective Hernia Implant (04/10/2025)New Bard Hernia Mesh Lawsuits Continue To Be Filed Following Global Settlement (04/03/2025)
Eliquis More Effective At Preventing Recurring Blood Clots, Embolism, Than Xarelto: Study December 22, 2021
Eliquis Useful In Preventing Blood Clots, But Side Effects Include Major Bleeding Risks: Study December 26, 2018
Lawyers To Select 50 Suboxone Dental Lawsuits for Next Phase of MDL Bellwether Discovery (Posted: today) As lawyers continue to review records on more than 500 Suboxone tooth decay lawsuits, the MDL judge has outlined the process for identifying a smaller group that will move into the next discovery phase. MORE ABOUT: SUBOXONE TOOTH DECAY LAWSUIT500 Suboxone Tooth Decay Cases Randomly Selected for Bellwether Record Collection Pool (04/24/2025)Status of Suboxone Tooth Loss Lawsuits To Be Reviewed at MDL Conference (04/16/2025)Prenatal Opioid Exposure May Result in Smaller Brains Among Newborns: Study (04/14/2025)
Hair Relaxer Lawsuits MDL Judge Seeks Status Report on Discovery Proceedings (Posted: yesterday) A federal judge wants lawyers involved in hair relaxer lawsuits to provide an update this week on the status of discovery proceedings for a pool of cases being considered for bellwether trial dates. MORE ABOUT: HAIR RELAXER LAWSUITFormaldehyde Found in Range of Personal Care Products Used Primarily by Black and Latina Women (05/14/2025)Lawyers Selected 32 Hair Relaxer Lawsuits for Bellwether Discovery in MDL (05/13/2025)Hair Relaxer Settlement Master Appointed To Oversee Negotiations To Resolve Cancer Lawsuits (04/29/2025)
Covidien Parietex Optimized Composite (PCOx) Hernia Mesh Lawsuits To Be Prepared for Trial (Posted: yesterday) Two Covidien Parietex Optimized Composite hernia mesh lawsuits have been chosen to be prepared to potentially serve as the third Covidien hernia mesh bellwether trial. MORE ABOUT: HERNIA MESH LAWSUITSecond Bellwether Trial in Covidien Hernia Mesh Lawsuit MDL Set for July 2026 (05/14/2025)Covidien Mesh Lawsuit Set For Trial in Feb. 2026, Over Defective Hernia Implant (04/10/2025)New Bard Hernia Mesh Lawsuits Continue To Be Filed Following Global Settlement (04/03/2025)